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Background and aim: Evidence exists for the pathogenic role of the enteric flora in inflammatory bowel
disease. Probiotics contain living microorganisms which exert health effects on the host. We compared the
efficacy in maintaining remission of the probiotic preparation Escherichia coli Nissle 1917 and established
therapy with mesalazine in patients with ulcerative colitis.
Patients and methods: In total, 327 patients were recruited and assigned to a double blind, double
dummy trial to receive either the probiotic drug 200 mg once daily (n = 162) or mesalazine 500 mg three
times daily (n = 165). The study lasted for 12 months and patients were assessed by clinical and
endoscopic activity indices (Rachmilewitz) as well as by histology. The primary aim of the study was to
confirm equivalent efficacy of the two drugs in the prevention of relapses.
Results: The per protocol analysis revealed relapses in 40/110 (36.4%) patients in the E coli Nissle 1917
group and 38/112 (33.9%) in the mesalazine group (significant equivalence p= 0.003). Subgroup
analyses showed no differences between the treatment groups in terms of duration and localisation of
disease or pretrial treatment. Safety profile and tolerability were very good for both groups and were not
different.
Conclusions: The probiotic drug E coli Nissle 1917 shows efficacy and safety in maintaining remission
equivalent to the gold standard mesalazine in patients with ulcerative colitis. The effectiveness of probiotic
treatment further underlines the pathogenetic significance of the enteric flora.
U
lcerative colitis (UC) is a chronic relapsing disease. The
aims of treatment are induction of remission and
prevention of relapses. Guidelines1 2 recommend ami-
nosalicylates for maintenance treatment. Aminosalicylates
exert various effects on leukotrienes, cytokines, and oxygen
radicals.3 Their mode of action in UC remains unclear. It is
suggested that the sum of their anti-inflammatory activities
constitutes their therapeutic principle. Thus maintenance
treatment with aminosalicylates is only effective when
inflammation starts, but not in the non-inflamed gut.
Growing evidence exists for a role of the intestinal
microflora in the pathogenesis of inflammatory bowel disease
(IBD). Findings from genetically engineered animal models
as well as clinical observations have elucidated the impor-
tance of commensal bacteria.4–6 Antibacterial treatment
showed some beneficial effects7 8 but the use of antibiotics
is limited. Therefore, treatment with probiotics has been
proposed.
Probiotics are viable non-pathogenic microorganisms that
confer health benefits to the host by improving the microbial
balance of the indigenous microflora.9 Apart from anecdotal
experience, two controlled studies with the probiotic bacterial
strain Escherichia coli Nissle 1917 (EcN) in UC already
exist.10 11 These trials showed no difference between the
relapse preventing effects of EcN and standard mesalazine.
However, some criticism was raised as to the validity of these
studies.12 13 The present study was undertaken to confirm that
the relapse preventing effects of probiotic therapy with EcN
and standard mesalazine are equivalent.
MATERIALS AND METHODS
The study was conducted according to the Helsinki
Declaration (revised version of Hong Kong) and adhered to
good clinical practice (GCP) guidelines. The study was
approved by the Ethikkommission der Ärztekammer
Nordrhein, Germany, as well as by the local ethics
committees of the participating centres. All patients received
material in their own language and gave written informed
consent. Patients were included in the study if aged 18–
70 years and diagnosed with UC in remission (clinical
activity index (CAI) (4, endoscopic index (EI) (4, and no
signs of acute inflammation on histological examination). In
addition, inclusion criteria comprised at least two acute
attacks of UC prior to the study and a duration of the current
remission of no longer than 12 months. Exclusion criteria
were: active UC; proctitis with up to 10 cm proximal spread;
Crohn’s disease; infectious colitis; severe accompanying
illnesses or major colonic surgery; use of antibiotics,
sulphonamides, steroids, or other therapies for UC at entry
into the trial; administration of EcN within the previous six
months before trial entry; as well as known intolerance to
salicylates.
Study medication
The investigational drug was a bacterial preparation for oral
use containing non-pathogenic Escherichia coli of strain Nissle
1917 (serotype O6:K5:H1). Capsules were enteric coated to
protect the microorganisms from gastric juice and contained
2.5–256109 viable bacteria (Mutaflor 100 mg; Ardeypharm
GmbH, Herdecke, Germany). The control preparation was
mesalazine, consisting of eudragit L coated 5-aminosalicylic
Abbreviations: UC, ulcerative colitis; IBD, inflammatory bowel disease;
EcN, Escherichia coli Nissle 1917; GCP, good clinical practice; CAI,
clinical activity index; EI, endoscopic index; ITT, intention to treat
















acid (Salofalk500 mg; Dr Falk Pharma GmbH, Freiburg,
Germany). The test group received one capsule of Mutaflor
100 mg once daily and one tablet of placebo three times daily
from day 1 to day 4, and two capsules of Mutaflor 100 mg
once daily and one tablet of placebo three times daily from
day 5 to the end of the study. The control group received one
capsule of placebo once daily and one tablet of Salofalk
500 mg three times daily from day 1 to day 4, and two
capsules of placebo once daily and one tablet of Salofalk
500 mg three times daily from day 5 to the end of the study.
No concomitant medication for UC was allowed through-
out the study.
Study design
This was a randomised, double blind, double dummy trial
comparing the relapse preventing effects and safety of a
bacterial preparation containing viable EcN and mesalazine
for 12 months in patients with UC in remission. The study
was conducted in 60 hospitals and private settings in 10
European countries (see list of participating investigators in
the appendix).
Randomisation was carried out in a double blind manner
in blocks of four patients using 1:1 allocation to the two
treatment groups. Only complete blocks of random numbers
were used for each centre. If patients were eligible for study
entry, they were assigned to random numbers (=patient
numbers) in ascending order within each centre according to
the chronological order of their randomisation and were
given the corresponding study medication.
Evaluation
Clinic visits were required at the start and end of the study as
well as after 1, 2, 3, 6, and 9 months of treatment.
The primary objective of the study was to compare the
number of patients experiencing a relapse of UC during the
12 month observation period between the two treatment
groups. Patients were classified as suffering a relapse when
all three of the following criteria were met: CAI .6 or an
increase in CAI of at least 3 points with CAI =4 being
exceeded at the same time; EI .4; and histological signs of
acute inflammation. CAI was defined according to
Rachmilewitz.14
At trial entry and at the end of the study, patients
underwent colonoscopy where biopsies were taken.
Endoscopic activity was assessed using a four point index14:
granularity, vascular pattern, vulnerability of mucosa, and
mucosal damage. All biopsies were examined by a single
pathologist using a four point scale.15
Secondary efficacy variables were the physician’s and
patient’s assessment of general well being and calculation
of a quality of life index.16 Additionally, time to relapse, CAI,
EI, and histological findings were documented.
Laboratory assessments, including erythrocyte sedimenta-
tion rate, C reactive protein, orosomucoids, blood counts,
liver enzymes, creatinine, serum iron, and serum albumin
were performed at trial entry and at the end of the study.
Incidence and severity of adverse events were reported
according to GCP for clinical trials of medication in the
European Community (91/507/EWG, CPMP/ICH/135/95).
Tolerance of the study medication was assessed on a four
point scale (very good, good, fair, poor), and patient
compliance was ascertained by pill counting.
Statistical analysis
The aim of the study was to statistically confirm one sided
equivalent efficacy of EcN and mesalazine in preventing
relapses of UC. Relapse rates were compared using the one
sided test of Farrington and Manning17: this tests the null
hypothesis that the difference between treatment groups is
greater than or equal to the upper equivalence margin D of
20% versus the alternative that the true difference is less than
20% (a=0.05; upper confidence limit 95%). Assuming a
12 month relapse rate of 30% under mesalazine treatment
and 35% under EcN treatment, to reach a statistical power of
80% at least n=127 patients were required in each treatment
group according to the sample size term for comparative
binomial trials with the null hypothesis of non-zero risk
difference.17 Two sets of patients were analysed: an intention
to treat population (ITT), including all patients who took at
least one dose of the study medication, and a per protocol
Table 1 Demographic data and prestudy clinical characteristics
Characteristic










Males 56.8% 52.7% 55.5% 50.9%
Age (y) (median (range)) 43 (19–69) 41 (19–82) 41 (19–69) 42 (19–74)
Localisation of UC
Sub-/total 26 (16.1%) 35 (21.3%) 16 (14.6%) 24 (21.5%)
Left sided 27 (16.7%) 35 (21.2%) 16 (14.5%) 26 (23.2%)
Distal 102 (63.0%) 88 (53.4%) 74 (61.8%) 57 (44.6%)
Duration of UC
(5 y 71 (43.8%) 84 (50.9%) 48 (43.6%) 52 (46.4%)
.5 y 91 (56.2%) 81 (49.1%) 62 (56.4%) 60 (53.6%)
Treatment before study (single/combined therapy)
Oral salicylates (mg)*
(1500 60 (37.4%) 68 (41.2%) 41 (37.3%) 46 (41.1%)
(3000 46 (28.4%) 47 (28.5%) 30 (27.3%) 35 (31.3%)
.3000 7 (4.3%) 7 (4.2%) 7 (4.6%) 4 (3.6%)
Clinical activity index 0.9 (1.2) 0.9 (1.2) 0.8 (1.0) 0.6 (1.0)
Endoscopic index 1.9 (1.6) 1.8 (1.5) 1.5 (1.2) 1.5 (1.3)
Histology (rectum)
No signs of active disease 77.8% 79.4% 94.5% 93.8%
Quality of life score 24 (4.1) 25.2 (3.7) 24.5 (3.9) 24.4 (4.0)
Smoker 10 (6.2%) 11 (6.7%) 8 (7.3%) 9 (8.0%)
UC, ulcerative colitis; EcN, Escherichia coli Nissle 1917; ITT, intention to treat population; PP, per protocol
population.
*Partly combined with steroids.
No significant differences between treatment groups.















population (PP). According to generally accepted standards
for equivalence and non-inferiority trials,18 primary analysis
of the main objective (difference in relapse rates) was based
on the PP population. Assuming 25% protocol violators, a
total number of 160 patients in each treatment group was
therefore planned.
Baseline comparability and statistical analysis of secondary
objectives was assessed using Fisher’s exact test (two sided;
a=0.05). In addition, Kaplan-Meier curves were plotted. If
no CAI or other parameter was documented at the individual
study end, the ‘‘last observation carried forward’’ method
was applied. Results are given as mean (SD). Statistical tests
were executed using SPSS software package version 10.0
under the Microsoft Windows NT operating system. For




In total, 327 patients were enrolled and randomised to either
the EcN preparation (n=162) or mesalazine (n=165). The
two patient groups were matched with regard to demo-
graphic, clinical, and pretreatment characteristics (table 1).
The time gap between the end of the last relapse before the
study and entry into the study was not longer than four
weeks in 11.1% of patients receiving EcN and in 9.1%
receiving mesalazine, and not longer than three months in
25.9% and 25.5% of EcN and mesalazine patients, respec-
tively. All 327 randomised patients received at least one dose
of the study medication and thus were included in the ITT
and safety analysis set.
Before unblinding the study, a steering committee assessed
protocol violations in 105/327 (32.1%) patients. Major
protocol deviations comprised violation of inclusion criteria
(CAI (4, EI (4, and no signs of acute inflammation on
histological examination) (32 patients in both groups),
premature discontinuation of the study without relapse (see
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Figure 1 Number of patients in the
study at the time of clinical visits and at
the final examination.
Table 2 Reasons for premature discontinuation of the study
Reason for premature discontinuation* EcN (n = 162) Mesalazine (n = 165)
Deterioration of disease (relapse not included) 1 (0.6%) 1 (0.6%)
Newly emerged exclusion criterion during study 4 (2.5%) 2 (1.2%)
Patient’s request 13 (8.0%) 9 (5.5%)
Adverse events 3 (1.9%) 6 (3.6%)
Insufficient patient compliance 6 (3.7%) 6 (3.6%)
Insufficient patient cooperation (diary) 6 (3.7%) 3 (1.8%)
Patient did not appear anymore 2 (1.2%) 5 (3.0%)
Other reasons 1 (0.6%) 2 (1.2%)
Patients with premature discontinuation 19 (11.7%) 20 (12.1%)
*Multiple reasons possible.














































Figure 2 Proportion of patients experiencing a relapse of ulcerative
colitis in the Escherichia coli Nissle 1917 (EcN) and mesalazine groups.















point (EcN 29 patients, mesalazine 24 patients). Accordingly,
the PP analysis set comprised 222 patients (EcN 110,
mesalazine 112). Mean duration of the study observation
period was 250 (144) (median 357) days in the EcN group
and 287 (125) (median 360) days in the mesalazine group.
The number of patients in the study at the scheduled visits is
shown in fig 1. Premature discontinuation of the study for
reasons other than relapse of disease occurred in 39/327
(11.9%) patients (in 19/162 (11.7%) patients in the EcN
group and in 20/165 (12.1%) patients in the mesalazine
group) (table 2). Newly emerged exclusion criteria during
the study were start of concomitant medication in four
patients on EcN. One patient on mesalazine became afraid of
5-aminosalicylic acid (5-ASA) and another patient under-
went cardiac surgery.
Relapse (primary objective)
PP analysis revealed relapse in 40/110 (36.4%) patients in the
EcN group and in 38/112 (33.9%) patients in the mesalazine
group (fig 2), resulting in significant equivalence between the
two groups (p=0.003). The corresponding one sided upper
95% confidence limit for the difference in treatment was
12.8% (that is, within the equivalence range of 20%).
Figure 3 depicts the probability of remaining in remission
by Kaplan-Meier curves. Median time to relapse in the EcN
group could not be calculated due to the large number of late
censorings. In the mesalazine group it was 386 days.
ITT analysis confirmed these results, showing a relapse rate
of 45.1% in the EcN group and 37.0% in the mesalazine group
(significant equivalence p=0.013). The upper limit of the
95% confidence interval for the difference in treatment was
16.9%.
Subgroup analyses (secondary objectives)
All subgroup analyses were performed in the ITT population.
CAI increased in all patients by 1.8 (3.4) points over the study
period, showing a slightly larger increase in the EcN group
(2.4 (3.7)) than in the mesalazine group (1.2 (3.0)). No
differences were observed in EI or histology between the start
and end of the study (fig 4). Table 3 lists relapse rates with
regard to duration, localisation, and pretrial treatment. There
were no significant differences between the treatment groups
for any of these characteristics. Quality of life scores on
admission were 24.5 (3.9) in the EcN group and 24.4 (4.0) in
the mesalazine group. Respective values after 12 months
were 24.3 (5.2) and 25.1 (3.9). No significant changes
occurred during the 12 month observation period.
Safety and tolerance
As rated by the patients, overall tolerance was very good or
good in the EcN group in 80.0% and in the mesalazine group
in 86.0%. According to the physician’s assessment, the
respective values were 85.1% and 90.3%.
Discontinuation of the study medication due to adverse
events (relapse included) occurred in 22 (6.7%) patients (11
(6.8%) in the EcN group and 11 (6.9%) in the mesalazine
group). Most frequent reasons were gastrointestinal disorders
such as bloody stools, nausea, diarrhoea, mucous secretion
(EcN 4.3%, mesalazine 4.2%), and abdominal pain (EcN
0.6%, mesalazine 2.4%).
Generally, no unexpected drug reactions occurred during
the study. No deaths but 17 serious adverse events were
reported in 13/327 (4%) patients (EcN 7, mesalazine 6). Each
serious adverse event occurred only once.
Adverse events were reported in 68/162 (42.0%) patients
treated with EcN and in 58/165 (35.2%) patients treated with
mesalazine. Many adverse events reflect symptoms common
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Figure 3 Probability of remaining in remission in the Escherichia coli




















































































Figure 4 Endoscopic index and
histology at the start and end of the
study in the Escherichia coli Nissle
1917 (EcN) and mesalazine groups.















and abdominal pain (8.5%). The most frequent non-
intestinal adverse events were viral infections (EcN 4.9%,
mesalazine 4.2%), nausea (3.1%, 3.0%) and headache (1.9%,
0.6%). Laboratory tests showed no significant alterations.
DISCUSSION
Most controlled trials are designed to test differences in
efficacy. In contrast, our trial was aimed at proving
equivalence. Indeed, we demonstrated that the probiotic
EcN provides significantly equivalent efficacy in preventing
relapses of UC and is not inferior to the established gold
standard mesalazine. This result was not only confirmed by
statistical analysis of the PP population, which is preferred in
equivalence studies,18 but also by ITT analysis.
Therapeutic efficacy is usually demonstrated by superiority
in a placebo controlled trial. In serious disease however when
effective therapy exists that has already been tested by
comparison with placebo, additional placebo controlled trials
may be considered unethical.18 A meta-analysis19 reviewed 16
studies of maintenance therapy involving 2341 patients with
UC. In four of these 16 trials, preparations containing 5-ASA
were compared with placebo; in the remaining 12 studies
sulphasalazine was compared. 5-ASA was observed to be
significantly more effective than placebo in all dosage
subgroups (,1 g/day, 1–1.9 g/day, >2 g/day). A dose depen-
dent trend was not observed.19 Indeed, some studies
comparing at least two doses were performed showing
mainly negative or conflicting results20: Pentasa 3 g/day was
not superior to 1.5 g/day; balsalazide 4 g/day was better than
2 g/day; balsalazide 6 g/day was better than 3 g/day in one
study but in another trial was similarly effective; and two
studies with olsalazine reached different conclusions. Thus
superior efficacy of doses higher than 1.5 g/day has not been
established.20 It can be stated that mesalazine 1.5 g/day
presently reflects the standard in the prevention of UC
relapses and thus it qualifies as a control in an equivalence
trial.
Previous studies on EcN were criticised12 13 for several
reasons—for example, short observation period10 or hetero-
geneity of patients and outcome parameters.11 The present
trial considered this critique and followed actual standards.
The observation period was 12 months, only patients with UC
in remission were included, and the clinical outcome was
assessed by well established endoscopic and histological
activity indices resulting in a low relapse rate for the
mesalazine group comparable with previous publications.19
A total of 327 patients were included to achieve a statistical
power sufficient to test for equivalence in a one sided set.
Most likely, IBD is caused by an unrestrained inflamma-
tory response to as yet undefined agents. Although precise
identification of the antigenic stimuli has not been deter-
mined, the intestinal microflora represents a likely cul-
prit.4 21 22 To manipulate the resident gut bacteria therefore
seems to offer a rational approach to maintaining remission
in IBD. One way of doing this, which has gained credence
over recent years, is by using probiotics.23
Mechanisms which may account for probiotic activity
include production of antimicrobial agents, inhibition of
adhesion of pathogens, and influence on mucosal barrier
function.13 It was reported that inhibition of nuclear factor kB
could be mediated by probiotic microorganisms.24 The
properties of EcN are well characterised25 and its genome
has been extensively analysed.26 It carries non-pathogenic
adhesion molecules. A specific lipopolysaccharide renders it
immunogenic without showing any immunotoxic proper-
ties.27 Immunomodulating activity was demonstrated for
specific immune responses as well as for induction of non-
specific natural immunity in preterm infants.28 EcN develops
antagonistic activity against enterobacteria such as Salmonella
enteritidis, Shigella dysenteriae, Yersinia enterocolitica, and Vibrio
cholerae.29 30 It prevents invasion of Salmonella typhimurium
into intestinal cells,31 inhibits adhesion and invasion of
adherent invasive E coli,32 and reduces concentrations of
mucosa associated colonic microflora constituents in UC.33
EcN is safe. Molecular genetics as well as functional
analyses have revealed that EcN does not produce any
virulence factors or carry any genes for pathogenicity traits.34
It does not bear genes for antibiotic resistance, transferable
genes or plasmids, and does not take up foreign pathogenic
DNA. No formation of enterotoxins, cytotoxins, or haemo-
lysins has been observed and there is no serum resistance.25 26 29
Clinical studies have demonstrated a favourable safety
profile for EcN compared with placebo,35 36 mesalazine,10 11
and lactulose.37 Our study confirms this excellent safety and
tolerance record.
There are other controlled studies with different probiotics.
Relapse prevention with Lactobacillus GG tested negatively for
maintenance therapy in surgically induced remission of
Crohn’s disease38 but a small study showed positive results
when Saccharomyces boulardii was added to mesalazine.39
Inflammation of the ileal pouch constructed after proctocol-
ectomy and ileoanal anastomosis in patients with UC is of
particular interest because bacterial growth seems to be of
pivotal pathophysiological significance. Cases successfully
treated with EcN have been reported.40 A formulation
comprising eight different probiotic bacteria demonstrated
convincing therapeutic effects in primary prevention41 and
chronic pouchitis.42 In an uncontrolled study, this preparation
was able to colonise the gut and maintain remission in
patients with UC.43
Table 3 Relapse rates according to clinical characteristics (intention to treat population)
Characteristic
EcN Mesalazine
% n % n
Duration of UC
,5 y 46.5 33/71 32.1 27/84
.5 y 44.0 40/91 42.0 34/81
Localisation of UC
Sub-/total 46.2 12/26 34.3 12/35
Left sided 63.0 17/27 31.4 11/35
Distal 41.2 42/102 40.9 36/88
Pretreatment
Oral salicylates* 45.1 51/113 37.7 46/122
UC, ulcerative colitis; EcN, Escherichia coli Nissle 1917.
*Partly combined with steroids.
No significant differences between treatment groups.















In conclusion, the use of probiotics in IBD is in accordance
with its pathogenesis. They may prevent induction of
inflammatory reactions. EcN shows therapeutic efficacy and
safety in maintaining remission in UC. It can be considered
as an alternative to mesalazine.
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Ochsenkühn; Städtisches Klinikum Friedrichstadt, Dresden:
H Porst; Krankenhaus Tabea, Hamburg: A Raedler;
University Hospital, Erlangen: M Raithel; Krankenhaus
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